Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT00539773
NCT00539773CompletedNot Applicable

Phase II Trial of Concurrent Administration of Intravesical BCG & Interferon in the Treatment and Prevention of Recurrence of Superficial Transitional Carcinoma of the Urinary Bladder

King Faisal Specialist Hospital & Research Center0 sites10 target enrollmentStarted: September 1, 2007Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Not Applicable
Status
Completed
Enrollment
10
Primary Endpoint
Efficacy
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Phase II Trial of concurrent administration of intravesical BCG & Interferon in the treatment and prevention of recurrence of superficial transitional carcinoma of the urinary bladder.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Patients with superficial transitional carcinoma of the urinary bladder

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Efficacy

Time Frame: overall

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Dr. Naeem A. Chaudhri

Principal Investigator

King Faisal Specialist Hospital & Research Center

Similar Trials

Completed
Phase 2
BCG Plus Interferon Alfa 2b in Treating Patients With Bladder CancerBladder Cancer
NCT00004122Roswell Park Cancer Institute
Not yet recruiting
Phase 1
A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder CancerBladder Cancer
NCT06255964SUNHO（China）BioPharmaceutical CO., Ltd.236
Completed
Phase 2
Intravesical Epirubicin Plus BCG to Prevent the Recurrence of Transitional Cell Carcinoma of BladderBladder Neoplasms
NCT00343356LanZhou University138
Unknown
Phase 1
Pegylated Interferon and Entecavir Combination in Chronic Hepatitis B (CHB)Chronic Hepatitis B
NCT01589952Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh20
Completed
Phase 2
Safety Study of Pegylated Interferon Lambda Plus Single or 2 Direct Antiviral Agents With RibavirinHepatitis C
NCT01309932Bristol-Myers Squibb165
Phase II Trial of Concurrent... | Clinical Trial